[Form 4] MaxCyte, Inc. Insider Trading Activity
Erck Stanley C, a director of MaxCyte, Inc. (MXCT), purchased 100,000 shares of the company’s common stock on 08/13/2025. The Form 4 shows the purchases were coded as P (purchase) and were made at prices ranging from $1.29 to $1.44, with a reported price entry of $1.3722. After the transactions the reporting person directly beneficially owned 398,328 shares. The filer notes the shares were bought in multiple transactions and offers to provide a detailed breakdown of the number of shares bought at each price upon request. No derivative holdings are reported on the form.
Erck Stanley C, direttore di MaxCyte, Inc. (MXCT), ha acquistato 100,000 azioni del capitale sociale della società il 08/13/2025. La Form 4 indica che gli acquisti sono stati codificati come P (acquisto) e sono stati effettuati a prezzi compresi tra $1.29 e $1.44, con un prezzo registrato di $1.3722. Dopo le operazioni la persona segnalante deteneva direttamente beneficiariamente 398,328 azioni. Il dichiarante precisa che le azioni sono state acquistate in più transazioni e si rende disponibile a fornire, su richiesta, il dettaglio del numero di azioni acquistate a ciascun prezzo. Nessuna posizione in derivati è riportata nel modulo.
Erck Stanley C, director de MaxCyte, Inc. (MXCT), compró 100,000 acciones comunes de la empresa el 08/13/2025. El Form 4 muestra que las compras fueron codificadas como P (compra) y se realizaron a precios que oscilaron entre $1.29 y $1.44, con un precio registrado de $1.3722. Tras las transacciones, la persona informante poseía directamente de forma beneficiaria 398,328 acciones. El declarante señala que las acciones se adquirieron en varias operaciones y ofrece proporcionar, bajo petición, el desglose detallado del número de acciones compradas a cada precio. No se informan tenencias de derivados en el formulario.
Erck Stanley C는 MaxCyte, Inc. (MXCT)의 이사로서 08/13/2025에 회사 보통주 100,000주를 매수했습니다. Form 4에는 매수가 P (매입)로 분류되었고, 매수가격은 $1.29에서 $1.44 범위였으며 신고된 가격은 $1.3722로 기재되어 있습니다. 거래 이후 보고자는 직접적으로 수익적 보유자 자격으로 398,328주를 보유하고 있었습니다. 제출인은 주식이 여러 건의 거래로 나누어 매수되었으며, 요청 시 각 가격에서 매수된 주식 수의 상세 내역을 제공하겠다고 밝혔습니다. 양식에는 파생상품 보유 내역이 보고되어 있지 않습니다.
Erck Stanley C, administrateur de MaxCyte, Inc. (MXCT), a acheté 100,000 actions ordinaires de la société le 08/13/2025. Le Form 4 indique que les achats ont été codés comme P (achat) et ont été effectués à des prix allant de $1.29 à $1.44, avec un prix déclaré de $1.3722. Après les opérations, la personne déclarante détenait directement à titre bénéficiaire 398,328 actions. Le déposant précise que les actions ont été achetées en plusieurs transactions et propose, sur demande, de fournir la ventilation détaillée du nombre d'actions achetées à chaque prix. Aucune détention de produits dérivés n'est signalée dans le formulaire.
Erck Stanley C, ein Direktor von MaxCyte, Inc. (MXCT), erwarb am 08/13/2025 100,000 Aktien des Stammkapitals des Unternehmens. Im Form 4 ist vermerkt, dass die Käufe als P (Kauf) codiert wurden und zu Preisen zwischen $1.29 und $1.44 getätigt wurden, mit einem gemeldeten Preis von $1.3722. Nach den Transaktionen besaß die meldende Person unmittelbar wirtschaftlich 398,328 Aktien. Der Einreicher weist darauf hin, dass die Aktien in mehreren Transaktionen erworben wurden und bietet auf Anfrage eine detaillierte Aufschlüsselung der Anzahl der zu jedem Preis gekauften Aktien an. Im Formular sind keine Derivatpositionen angegeben.
- Director purchase of 100,000 shares demonstrates insider acquisition reported on Form 4
- Direct beneficial ownership increased to 398,328 shares, disclosed explicitly
- Purchase price range disclosed ($1.29–$1.44) and an aggregate price entry of $1.3722
- Filer offers to provide detailed price breakdowns for the multiple execution prices
- None.
Insights
Director purchased 100,000 MXCT shares at low-single-digit dollar prices; increases direct holding to 398,328 shares.
The Form 4 documents a straightforward open-market purchase coded as a purchase (P) on 08/13/2025 totaling 100,000 common shares at prices between $1.29 and $1.44, with an indicated price of $1.3722. The increase in direct beneficial ownership to 398,328 shares is factual and verifiable from the filing. This transaction is a clear insider buy but its materiality relative to company capitalization cannot be assessed from the form alone.
A director-level open-market purchase is reported; disclosure is complete with a footnote offering granular price details.
The filing identifies the reporting person as a director and discloses a purchase across multiple executions with a disclosed price range and an asserted aggregate price entry of $1.3722. The form is signed by an attorney-in-fact, and the filer commits to provide underlying execution price details if requested. From a governance perspective, the filing meets Section 16 disclosure requirements without indicating any loan, grant, or derivative arrangements.
Erck Stanley C, direttore di MaxCyte, Inc. (MXCT), ha acquistato 100,000 azioni del capitale sociale della società il 08/13/2025. La Form 4 indica che gli acquisti sono stati codificati come P (acquisto) e sono stati effettuati a prezzi compresi tra $1.29 e $1.44, con un prezzo registrato di $1.3722. Dopo le operazioni la persona segnalante deteneva direttamente beneficiariamente 398,328 azioni. Il dichiarante precisa che le azioni sono state acquistate in più transazioni e si rende disponibile a fornire, su richiesta, il dettaglio del numero di azioni acquistate a ciascun prezzo. Nessuna posizione in derivati è riportata nel modulo.
Erck Stanley C, director de MaxCyte, Inc. (MXCT), compró 100,000 acciones comunes de la empresa el 08/13/2025. El Form 4 muestra que las compras fueron codificadas como P (compra) y se realizaron a precios que oscilaron entre $1.29 y $1.44, con un precio registrado de $1.3722. Tras las transacciones, la persona informante poseía directamente de forma beneficiaria 398,328 acciones. El declarante señala que las acciones se adquirieron en varias operaciones y ofrece proporcionar, bajo petición, el desglose detallado del número de acciones compradas a cada precio. No se informan tenencias de derivados en el formulario.
Erck Stanley C는 MaxCyte, Inc. (MXCT)의 이사로서 08/13/2025에 회사 보통주 100,000주를 매수했습니다. Form 4에는 매수가 P (매입)로 분류되었고, 매수가격은 $1.29에서 $1.44 범위였으며 신고된 가격은 $1.3722로 기재되어 있습니다. 거래 이후 보고자는 직접적으로 수익적 보유자 자격으로 398,328주를 보유하고 있었습니다. 제출인은 주식이 여러 건의 거래로 나누어 매수되었으며, 요청 시 각 가격에서 매수된 주식 수의 상세 내역을 제공하겠다고 밝혔습니다. 양식에는 파생상품 보유 내역이 보고되어 있지 않습니다.
Erck Stanley C, administrateur de MaxCyte, Inc. (MXCT), a acheté 100,000 actions ordinaires de la société le 08/13/2025. Le Form 4 indique que les achats ont été codés comme P (achat) et ont été effectués à des prix allant de $1.29 à $1.44, avec un prix déclaré de $1.3722. Après les opérations, la personne déclarante détenait directement à titre bénéficiaire 398,328 actions. Le déposant précise que les actions ont été achetées en plusieurs transactions et propose, sur demande, de fournir la ventilation détaillée du nombre d'actions achetées à chaque prix. Aucune détention de produits dérivés n'est signalée dans le formulaire.
Erck Stanley C, ein Direktor von MaxCyte, Inc. (MXCT), erwarb am 08/13/2025 100,000 Aktien des Stammkapitals des Unternehmens. Im Form 4 ist vermerkt, dass die Käufe als P (Kauf) codiert wurden und zu Preisen zwischen $1.29 und $1.44 getätigt wurden, mit einem gemeldeten Preis von $1.3722. Nach den Transaktionen besaß die meldende Person unmittelbar wirtschaftlich 398,328 Aktien. Der Einreicher weist darauf hin, dass die Aktien in mehreren Transaktionen erworben wurden und bietet auf Anfrage eine detaillierte Aufschlüsselung der Anzahl der zu jedem Preis gekauften Aktien an. Im Formular sind keine Derivatpositionen angegeben.
FAQ
What transaction did Erck Stanley C report for MXCT?
At what prices were the MXCT shares purchased?
How many MXCT shares does the reporting person own after the transaction?
Does the Form 4 report any derivative securities for MXCT?
Who signed the Form 4 filing for this transaction?
